Skip to main content
Fig. 5 | EJNMMI Research

Fig. 5

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 5

a, b Survival percentage after 213Bi-DOTATATE therapy without (−) or with (+) l-lysine (35 mg) pre-injection in nontumor-bearing mice; cohort low-dose(−) received cumulatively 13.0 ± 1.6 MBq, low-dose(+) 13.2 ± 0.9 MBq, medium-dose(−) 20.7 ± 0.8 MBq, medium-dose(+) 21.7 ± 1.9 MBq, high-dose(−) 28.7 ± 1.2 MBq, and high-dose(+) 28.3 ± 0.8 MBq (n = 8/cohort). Control animals received 4 × 0.3 nmol DOTATATE (n = 8)

Back to article page